Veracyte’s (VCYT) “Buy” Rating Reaffirmed at Guggenheim
Guggenheim reaffirmed their buy rating on shares of Veracyte (NASDAQ:VCYT – Free Report) in a report published on Tuesday morning,Benzinga reports. The firm currently has a $45.00 price objective on the biotechnology company’s stock. A number of other brokerages have also weighed in on VCYT. Needham & Company LLC reissued a “buy” rating and set […]
